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Since its first human use, dated back to 1987 (1), 
radioimmunotherapy (RIT) of non-Hodgkin (NHL) 
lymphomas has undergone many vicissitudes, and we might 
be not too far from the truth by affirming that this is not 
the best time for it (2). As a matter of fact, the worldwide 
enthusiasm following the approval, at the beginning of this 
century, of the first two RIT compounds, 90Y-ibritumomab-
tiuxetan (Zevalin®) and 131I-tositumomab (Bexxar®) for 
relapsed/refractory indolent NHL, was tempered by 
the success of new chemotherapy agents (3) and of the 
rituximab maintenance strategies (4). Moreover, in case of 
relapse after optimized rituximab-including treatments, RIT 
showed a reduced efficacy both in aggressive and indolent 
NHLs (5,6). In addition, the absence of randomized phase 
III studies comparing RIT head-to-head with other agents 
and the physicians’ natural reluctance to refer patients to 
radionuclide treatments, have played in synergy against 
its use. At present, RIT is underused (Figure 1) and, in 
February 2014, this has led to the withdrawal of Bexxar® 
from the US market.
Yet, RIT is by far the most effective and least toxic single 
treatment for NHL, and it is largely preferred by patients 
over other therapeutic options (7-9); in fact, none of the 
available anti-cancer agents would be able to produce as 
high as 87% ORR (including 56% CR/Cru) or 95% ORR 
(including 75% CR/Cru) after a single infusion, as obtained 
with frontline Zevalin® or Bexxar®, respectively (7,8). 
Interestingly, nuclear medicine has the intrinsic potential 
of allowing pre and post-therapeutic in-vivo biodistribution 
studies, which might inform the therapeutic infusion of 
RIT. By applying computational analysis on radioactivity 
distribution in organs or tumor lesions over time, internal 
dosimetry allows for obtaining dose calculations in these 
body compartments (Figure 2). Indeed, doses to organs 
and target lesions can vary intra and inter-patients because 
of the influence of all possible physical and biological 
variables in RIT, such as scheme of RIT fractionation, 
amount of antibody preloading, changes in size and biology 
etc. Unfortunately, such dosimetry studies are seldom 
accomplished in clinical practice, thought they might 
help to evaluate the effect of all these variables on RIT 
efficacy and toxicity, pursuing patient-specific treatment 
optimization.
Planar dosimety using a tracing amount of 131I-labeled 
antibody is part of the standard protocol for Bexxar® 
infusion, where the therapeutic administered activity is 
planned on a single-patient basis in order to keep the 
resulting total-body dose (TBD) within a predetermined 
limit (i.e., <75 cGy or <65 cGy in patients with platelet 
counts ≥ or ≤150,000/mL, respectively). As a result, the 
range of administered therapeutic activity per single patient 
is wide, that is between 47 and 212 mCi (1.74–7.8 GBq), 
median 91 mCi (3.36 GBq) (10) .  Interest ingly,  a 
significantly longer duration of response was shown for 
patients receiving higher TBD (>65 cGy) if compared to 
patients receiving less than 55 cGy (11). 
Conversely, the activity to be administered in RIT with 
the radiometal conjugate 90Y-ibritumomab-tiuxetan takes 
into account patient weight and platelet blood count only, 
and no optimization based on pre-therapeutic dosimetry is 
considered. 
The choice of avoiding dosimetry in case of Zevalin® 
has several reasons. First, the biodistribution of radio-
metal conjugates is generally thought to be better 
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predictable than that of radio-halogens. Second, dosimetry 
of 90Y-ibritumomab is complicated by the technical 
impossibility of obtaining γ-camera images by means of 
the pure β-emitter 90Y, which requires the labeling of 
ibritumomab with a γ-emitting surrogate, such as 111In. 
Third, and probably of greater importance, the marketing 
of RIT compounds has preceded many recent technical 
and theoretical achievements of internal dosimetry 
which, when RIT was developed, was just not advanced 
enough to match clinical needs and expectations. In fact, 
radiobiological modeling has only recently been applied 
to radionuclide treatments and is continuously evolving 
as new questions arise from therapies implying different 
Figure 1 Distribution over time of a total of 101 radioimmunotherapy 
treatments with 90Y-ibritumomab-tiuxetan (Zevalin®) performed at 
Sant’Andrea University Hospital of Rome, Italy, between July 2006 
and October 2015.
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Figure 2 Isodose map at the pixel level of an axillary lymphoma 
lesion of follicular origin obtained by sequential planar γ-camera 
imaging after the injection of a tracing amount of 111In-Zevalin. 
Dose values are reported in Gy. 
physical and biological effects (12-14). In addition, only 
the breakthrough of hybrid SPECT/CT cameras has 
allowed accounting for errors and spatial heterogeneities in 
dose calculations, facilitating patient-specific voxel-based 
dosimetry and implementing radiobiological modeling (15). 
As such, standard planar dosimetry is no longer a good 
model for optimizing RIT efficacy, and three-dimensional, 
voxel-based dosimetry is warranted. Only recently three 
dimensional dosimetry and radiobiological modeling have 
been applied to RIT: a few reports have been published 
supporting a dose-response relationship for NHL nodal 
lesions treated with Bexxar® (16), while tumor voxel-based 
dosimetry of Zevalin® is still at its beginning (17,18). 
In synthesis, much room does still exist for improvement 
of RIT efficacy and optimization of delivery and the feeling 
is that RIT is not only underprescribed but also underdosed. 
An excellent effort toward dose optimization in RIT 
is represented by a recently published paper from a 
cooperative international research group reporting on 
the efficacy and toxicity of 90Y-ibritumomab-tiuxetan 
delivered in two fractions as frontline therapy in patients 
with follicular lymphoma (FL) (19). From the 76 recruited, 
a total of 72 patients entered the final protocol; fifty-five 
patients (76%) received both infusions. Eight and four 
patients did not proceed with the second RIT infusion 
because of bone marrow toxicity (BM) and treating 
physician’s discretion, respectively. Additionally, 4 patients 
developed mouse antibodies (HAMA) after the first cycle 
and one patient did not undergo the second infusion for 
underlining psychiatric disease. Most patients (78%) were 
stage III/IV; 44% patients had high-risk FLIPI. Patients 
with more that 20% BM infiltration were pretreated with 
four weekly infusions of rituximab 375 mg/m2 and entered 
the study provided that <20% BM infiltration was achieved. 
RIT infusions were administered 8 weeks apart, 
unless otherwise indicated by s low BM recovery. 
90Y-ibritumomab-tiuxetan was given at 11.1 MBq/Kg and 
injected activities were capped at 888 MBq (24 mCi). 
Such protocol showed an excellent 95.8% ORR including 
69.4% CR/Cru, and a projected 3-year PFS of 58%. 
Interestingly, in contrast to previous observations, there 
was no significant difference in PFS between patients 
with tumor size < or >5 cm (65.4% vs. 50.2%, P=0.47). 
Hematological toxicity profile was acceptable: grade 4 
thrombocytopenia and neutrophenia occurred in 6.9% and 
8.3% of patients after the first infusion, increasing to 21.8% 
and 14.5% after the second infusion, respectively. After 
the second RIT, 8 (14.5%) patients received platelets and 
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the same number of patients received red cell transfusions. 
Two (2.8%) neutropenic sepses were observed in the entire 
cohort. It is worth reminding, however, that 8 patients (11% 
of the initial cohort) could not undergo the second RIT 
infusion because of prolonged BM suppression after the 
first treatment. 
Dose fractionation has a strong theoretical rationale both 
in external beam radiation therapy (EBRT) and in RIT 
since, according to the classical linear-quadratic model, it 
makes possible to increase the total dose delivered to tumor 
by decreasing normal tissue toxicity. An additional advantage 
of dose fractionation in RIT would be the possibility to 
achieve more uniform dose distributions within tumors by 
progressively reducing tumor size and improving blood 
supply (20). However, the same radiobiological principles 
do not necessarily apply identically to both EBRT and 
RIT, as the latter involves heterogeneous, continuous and 
continuously decreasing low-dose-rate radiation, which 
effects on cell killing have yet to be fully understood (21). 
As a matter of fact, it is interesting to note that non-targeted 
effects, including apoptosis, mutations, cell transformation, 
release of stress signals, are probably prevalent in RIT as 
they occur after low dose or low dose-rate irradiation (21). 
These so called “bystander” effects might not be fitted 
by linear or linear-quadratic models, rather they might 
saturate after a certain dose threshold, questioning the 
superior efficacy of the dose-fractionation vs. standard, 
single treatment approach in RIT, which indeed has yet to 
be experimentally determined in patients (21). In addition, 
there are other non-radiation dependent immunological 
effects of RIT which might help to explain the excellent 
response of some tumor to very low radiation burden. For 
example, it has been suggested that the benefit of RIT 
would be higher in patients with preserved T cell immunity, 
which might complement the effect of radiation by eliciting 
a cell-mediated toxicity against the mouse monoclonal 
antibodies used in RIT (22). 
Some responses to the radiobiological questions 
regarding efficacy of dose fractionation on tumor control 
in RIT might come from the study of Illidge et al. (19). A 
retrospective dosimetric analysis of 28 patients from this 
cohort revealed that organ absorbed doses were similar for 
both fractions and that an image-based, 3D method for BM 
dosimetry was predictive of hematological toxicity (23). 
Unfortunately, however, at the time of writing no data have 
yet been published on the results of tumor dosimetry in 
these patients. 
Given its complexity and all the reasons we briefly 
outlined above, not surprisingly dosimetry was only 
retrospectively analyzed and not used to inform treatment 
schedule in this trial. Therefore, important radiobiologic 
and immunologic questions still need to be addressed. 
Nonetheless, the study of Illidge and colleagues is 
encouraging and could potentially pave the way for 
the conception and design of future trials aiming at 
a radiobiological optimization of RIT delivery. With 
particular regard to tumor dose-effect relationships, there 
might be a bulk of relevant information arising from 
combined dosimetric, clinical and laboratory data of this 
study, which would be otherwise lost if not fully analyzed 
and discussed. In other words, this study might have still a 
lot to say on the effects of RIT. 
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